NCT06299111 (ROXI-CATH) is a Phase 2 clinical trial of REGN9933 in Venous Thromboembolism, sponsored by Regeneron Pharmaceuticals.

Who is sponsoring NCT06299111?

NCT06299111 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT06299111?

Interventions in NCT06299111: REGN9933, REGN7508, Placebo.

What condition does NCT06299111 study?

NCT06299111 studies Venous Thromboembolism.

Is NCT06299111 still recruiting?

NCT06299111 is currently completed. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT06299111: ROXI-CATH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Completed Phase 2 Last updated 13 April 2026

What this trial tests

Phase 2 trial testing REGN9933 in Venous Thromboembolism in 195 participants. Completed in 27 March 2026.

Timeline

20 September 2024

Primary endpoint
27 March 2026

27 March 2026

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	195
Start date	20 September 2024
Primary completion	27 March 2026
Estimated completion	27 March 2026
Sites	23 locations across United Kingdom, Israel, Romania, Canada, Bulgaria, United States

Drugs / interventions tested

REGN9933 — full drug profile →
REGN7508 — full drug profile →
Placebo

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.
Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2025 · cited 6× · PMID 40058879 · DOI 10.1093/ehjcvp/pvaf012
Factor XI antagonists: the discovery of the philosopher's stone?
De Vriese AS, Ledó N. · · 2024 · cited 4× · PMID 38742210 · DOI 10.1093/ckj/sfae106
New horizons in the pharmacological management of venous thromboembolism.
Verstraete A, Van Thillo Q, Vanassche T, Verhamme P. · · 2025 · PMID 40469483 · DOI 10.1002/hem3.70143
Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report.
Beyer-Westendorf J, Weber K, Eckart F, Laass MW, et al · · 2025 · PMID 40406075 · DOI 10.1055/a-2577-4474

Verify or expand the search:

Other trials of REGN9933

Trials testing the same drug.

NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
NCT07430956 — Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is · Phase 3 · not yet recruiting
NCT07175428 — Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation · Phase 2 · recruiting
NCT06444178 — Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, · Phase 1 · completed
NCT05618808 — A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants · Phase 2 · completed

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06299111 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06299111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing